NurExone Biologic Inc. Stock Toronto S.E.
Equities
ENER
CA29278Q1063
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 31.25M 42.72M |
---|---|---|---|---|---|
Net income 2024 * | -4M -5.47M | Net income 2025 * | -4M -5.47M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-5.28
x | P/E ratio 2025 * |
-5.28
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.95% |
Managers | Title | Age | Since |
---|---|---|---|
Lior Shaltiel
CEO | Chief Executive Officer | - | 21-03-31 |
Eran Ovadya
DFI | Director of Finance/CFO | - | 22-06-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jay Richardson
BRD | Director/Board Member | 78 | 22-01-02 |
Gadi Riesenfeld
BRD | Director/Board Member | 79 | 23-07-05 |
Yoram Drucker
CHM | Chairman | 59 | 19-12-31 |
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |